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Abstract 
 
Introduction: Despite active antiretroviral therapy (ART), community-acquired 
pneumonia (CAP) remains a major cause of morbidity and mortality among HIV-
infected patients, and incurs high health costs. 
 
Areas covered: This article reviews the most recent publications on bacterial CAP in 
the HIV-infected population, focusing on epidemiology, prognostic factors, microbial 
etiology, therapy, and prevention. The data discussed here were mainly obtained from 
a non-systematic review using Medline, and references from relevant articles. 
Expert Commentary: HIV-infected patients are more susceptible to bacterial CAP. 
Although ART improves their immune response and has reduced CAP incidence, these 
patients continue to present increased risk of pneumonia in part because they show 
altered immunity and because immune activation persists. The risk of CAP in HIV-
infected patients and the probability of polymicrobial or atypical infections are 
inversely associated with the CD4 cell count. Mortality in HIV-infected patients with 
CAP ranges from 6% to 15% but in well-controlled HIV-infected patients on ART the 
mortality is low and similar to that seen in HIV-negative individuals. Vaccination and 
smoking cessation are the two most important preventive strategies for bacterial CAP 
in well-controlled HIV-infected patients on ART.  
 
Keywords: Community-acquired pneumonia, bacterial pneumonia, HIV-infection 
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1. Introduction 
Community-acquired pneumonia (CAP) remains a major complication in human 
immunodeficiency virus (HIV)-infected patients, even in the era of combined 
antiretroviral therapy (ART)(1–5). Although the introduction of ART has drastically 
changed the epidemiology of pulmonary infections in HIV-infected patients, not all 
patients receive ART or show good compliance. In addition, the number of patients 
with unknown HIV infection remains high. 
In 2016, the Global Health Observatory (GHO) reported that 36.7 million people 
worldwide were living with HIV, almost 21 million people were receiving antiretroviral 
therapy by mid-2017 and approximately 1 million had died of HIV-related disease(1). 
Progressive CD4+ T-cell loss and changes in immunological status in untreated HIV-
infected persons comprise the main risk factors for developing other infectious 
diseases such as pneumonia, which often require admission to an intensive care unit 
(ICU)(6).  
Several studies have examined the microbial etiology and prognostic factors of CAP in 
HIV-infected patients(4–6). In general, HIV-infected persons have a 10-fold higher risk 
of developing bacterial pneumonia than HIV-negative persons(7,8). However, despite 
the high rate of bacterial pneumonia in HIV-infected patients, mortality rates are no 
higher than in patients without HIV infection(5,9,10). 
The aim of this article is to review the most recent relevant studies focusing on 
epidemiology, risk factors, etiology, treatment, prognosis and prevention of CAP in 
HIV-infected patients. 
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2.  Methods 
This article reviews the most recent publications relative to Community-Acquired 
Bacterial Pneumonia in Adult HIV-infected Patients, with a focus on epidemiology, risk 
factors, microbial etiology, microbiome, antibiotic therapy, prognosis and prevention. 
The data discussed in this review were mainly obtained from a non-systematic review 
using Medline, and references from relevant articles. 
Titles and abstracts were initially screened to identify relevant citations, which were 
then reviewed in full by all authors. All authors confirmed the inclusion of the 
identified publications. 
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3. Epidemiology 
The Global Burden of Disease study (2016) reported that lower respiratory tract 
infections are the third most common cause of death worldwide, exceeded only by 
ischemic heart disease and cerebrovascular disease(1). Similarly, statistics released by 
the World Health Organization (WHO) in 2015 indicated that 3.2 million of the 56.4 
million deaths worldwide in 2015 were caused by lower respiratory tract infections 
(LRTI), rendering them the most deadly communicable disease and the third leading 
cause of mortality(11). Bacterial CAP, Pneumocystis infection, and tuberculosis (TB) are 
the most frequent pulmonary infections in HIV-infected patients(6). The distribution of 
prevalence of these respiratory infections is associated with specific geographical 
areas. For example, in low- and middle-income regions, TB remains the main infection 
related to HIV-infected patients, whereas in high-income regions, bacterial CAP is most 
frequent in the HIV-infected population.  
An interesting study of pneumonia in individuals with and without HIV infection 
reported that its incidence in HIV-infected patients in the pre-ART era was 5.06 
hospitalizations per 100 person-years, compared with 3.46 hospitalizations per 100 
person-years in patients without infection. In the post-ART era the incidence was 1.97 
hospitalizations per 100 person-years in HIV-infected patients, and 0.59 
hospitalizations per 100 person-years in HIV-infected patients with CD4 cell count >500 
cell/ul; in patients without HIV infection, it was 0.63 hospitalizations per 100 person-
years(12). 
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The use of ART is clearly changing the epidemiology of bacterial CAP in HIV-infected 
patients. However, HIV infection remains a risk factor for pneumonia even in persons 
with high CD4+ cell counts. 
For example, in an epidemiological study of bacteraemic pneumococcal pneumonia, 
Grau et al.(13) reported an incidence of 2.41 episodes per 100 patient-years in pre-ART 
era patients, compared with 0.82 episodes per 100 patient-years in patients with ART.  
In an interesting RCT performed in the US(14), which compared the risk of bacterial 
pneumonia in HIV-infected patients with intermittent ART therapy and in patients with 
virologically suppressed HIV infection and receiving continuous ART, the authors 
reported that HIV-infected patients with predominantly off-ART therapy were over 
twice as likely to develop bacterial pneumonia (risk rate 2.8 per 100 person-years for 
those with fewer than 250 CD4 cells) compared with virologically-suppressed HIV-
infected patients (risk of 1.0 per 100 person-years for those with 500 or more CD4 
cells) in the multivariate analysis.  
As with the general population, Streptococcus pneumoniae (pneumococcus) is the 
main cause of bacterial CAP in HIV-infected patients. Pneumococcus is diagnosed in 
approximately 30% to 40% of CAP cases in HIV-infected patients with a defined 
etiology(4,15). In a recently published study on lower respiratory tract infection (LRTI) 
in a cohort of 2669 HIV-infected adults on ART, Lamas et al.(16) reported a LRTI 
incidence of 3.07 cases/100 patient-years. CAP was diagnosed in 14% (384) of cases. 
The same authors also reported that higher CD4 counts and undetectable viral loads 
were protective factors for CAP in the multivariate analysis, as were pneumococcal and 
influenza vaccinations. Despite effective ART, bacterial CAP is still frequent in HIV-
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infected patients(17,18), and mortality rates may be rising due to the prevalence of 
comorbidities in CAP patients(19). A prospective study(7) analyzing more than 18,000 
patients in 34 countries over the period 2006 to 2011 reported a pneumonia incidence 
of 0.53 cases/100 person-years. Similarly, in an Italian study, Mussini et al.(20) 
reported an incidence of bacterial CAP of 0.56 cases/100 person-years. 
More recently a study by O’Connor et al.(21) that investigated the effect of immediate 
initiation of ART on risk of severe bacterial infections in HIV-infected patients with CD4 
cell counts >500 cells per ml, and involved intercontinental patient data, reported that 
the incidence of severe bacterial infection including pneumonia ranges from 0.5 to 2.8 
per 100 person-years according to geographical region.  Bacterial pneumonia was 
present in 1.02% of the 4,685 patients: 0.6% of patients who received immediate ART 
presented bacterial pneumonia whereas 1.44% of patients in whom ART initiation was 
deferred presented bacterial CAP. 
In conclusion, CAP remain a major clinical problem in HIV-infected patients, even 
though we observed a reduced incidence after ART scale-up, and remains frequent 
even in HIV-infected patients on ART with high CD4+ cell counts. Overall, HIV-infected 
patients have a ten times higher risk of developing pneumonia than uninfected 
patients(19,22). 
4. Risk factors for CAP 
The specific risk factors for CAP in HIV-infected patients include active and passive 
smoking, alcoholism, older age (older than 65 years), intravenous drug use, 
comorbidities (chronic obstructive pulmonary disease, chronic liver disease, 
cardiovascular disease, chronic renal disease), low CD4 cell counts, detectable HIV viral 
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load, previous episode of pneumonia, and lower socioeconomic status (Table 1)(23). 
The prevalence of smoking in HIV-infected patients in general is very high – between 
42% and 46% in US and European studies, compared to 21% to 26% in the general 
population(24–26). Also, excessive alcohol consumption is common among HIV-
infected people and increases the risk of pulmonary disease such as pneumonia. 
Alcohol affects both innate and adaptive immune responses and causes 
immunosuppression; this explains why chronic alcohol consumption increases the 
incidence of bacterial and viral pneumonias in these patients. 
A study including data from 34 European countries(7) reported that the factors 
predisposing HIV-infected patients to develop severe bacterial non-AIDS infections 
were the presence of previous comorbidities, a previous episode of pneumonia, and 
malnutrition in  the adjusted multivariate analysis. 
An American study (27) reported that 10.8% of the approximately 50,000 incident HIV 
infections that occur annually in the USA affect people ≥50 years old. 
Immunosenescence refers to age-related immunological changes that reduce the 
efficiency of the adaptive and innate immune system, and it is responsible for 
deterioration in the response to infection and an increase in pathological disorders in 
the elderly population(28). 
Smoking impacts on the immune system’s capacity to mount an appropriate immune 
and inflammatory response to infections such as CAP, and this effect has also been 
observed in passive smokers(22,29,30). Some studies have suggested that there is an 
association between smoking and a poor virological and immunological response to 
ART(31–34). This was confirmed in a recent study by Hile et al.(35), who studied the 
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association between tobacco smoking and biomarkers of HIV disease progression, and 
found that recent tobacco smoking was independently associated with unsuppressed 
viral load (OR = 1.38) and a low CD4 cell count (OR = 1.12) in multivariate analyses 
controlling for sociodemographic and clinical characteristics. 
It has been reported that approximately 25% of HIV-infected patients have chronic 
obstructive pulmonary disease(36). In a recent age and sex-matched study on airway 
obstruction in 351 HIV-infected and 702 uninfected study participants, all smokers 
over 40 years of age, the authors found that HIV infection was independently 
associated with lower FEV1/FVC ratios in a multivariate analysis. They also reported 
that HIV was associated with an increased prevalence of airway obstruction, as 
measured by a prebronchodilator FEV1/FVC ratio less than 0.70 and a FEV1 value less 
than 80% of the theoretical value(37). 
In conclusion, the risk factors for CAP in HIV-infected patients are: smoking, 
alcoholism, advanced age, intravenous drug use, previous comorbidities, low CD4 cell 
counts, detectable HIV viral load, previous episode of pneumonia, and lower 
socioeconomic status. 
5. Principal pathogens involved in HIV-infected patients with CAP 
Despite advances in microbiological tests, microbial diagnosis is only achieved in 
approximately 50% of CAP cases. It is known that the bacterial etiology of pneumonia 
is similar in HIV-infected on ART and in uninfected patients(6,38). In a prospective 
observational study of 331 consecutive adult CAP cases in HIV-infected patients from 
Spain, Cillóniz et al.(4) described the microbial etiology in this population. According to 
these authors, S. pneumoniae (30%), P. jirovecii (13%), mixed etiology (11%), 
respiratory viruses (5%), Haemophilus influenzae (2%), and Staphylococcus aureus (2%) 
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were the most frequently detected microorganisms in the study population (Figure 1). 
Of these, S. pneumoniae was the most frequently observed microorganism in the 
group with a CD4+ cell count of ≥ 200 cell/mm3, while P. jirovecii was the most 
frequently occurring microorganism in the group with a CD4+ cell count of < 200 
cell/mm3 and in patients with HIV-RNA ≥ 200 copies/mL. The authors also reported 
that days of symptoms ≤5 (OR 2.6, 95% CI 1.5–4.4), cotrimoxazole prophylaxis (OR 2.0, 
95% CI 1.2–3.4), C-reactive protein level ≥22 mg/dL (OR 4.3, 95% CI 2.3–8.2), and 
hepatitis C-virus co-infection (OR 2.3, 95% CI 1.4–3.9) were predictors of bacterial CAP 
in the multivariate analysis, whereas female sex (OR 0.2, 95% CI 0.1–0.9), current 
smoking (OR 0.4, 95% CI 0.1–0.9), cotrimoxazole prophylaxis (OR 0.1, 95% CI 0.04–0.5), 
WBC count ≤ 4,000 x109 cells/L (OR 3.7, 95% CI 1.2–11.5), LDH ≥598 U/L (OR 12.9, 95% 
CI 4.2–39.7), and multilobar infiltration (OR 5.8, 95% CI 1.9–19.5) were predictors of P. 
jirovecii in the multivariate analysis. In this study HIV infection had been diagnosed 
prior to hospital admission in 83% of the patients and 51% of the patients were on 
ART; the remaining 17% of the patients were diagnosed with HIV infection during the 
pneumonia episode. 
In a study from Brazil in which the majority of patients had never used, had 
abandoned, or reported irregular use of ART, and 73% of patients presented < 200 CD4 
cells/mm3, the microbial etiology of 224 CAP cases in whom microbial diagnosis was 
plausible in 64% of cases was as follows(39): Pneumocystis jirovecii was the main 
agent, detected in 36% of cases, followed by Mycobacterium tuberculosis (20%), S. 
pneumoniae and Rhinovirus (15% each), influenza virus (10%), Mycoplasma 
pneumoniae (8%), and Chlamydophila pneumoniae (5%). The authors also reported 
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mixed infections, diagnosed in 34% of cases. These two studies showed differences in 
the distribution of pathogens in bacterial CAP according to the use of ART therapy.  
Data from South Africa showed that underlying HIV infection is the most important risk 
condition for LRTI hospitalization with a prevalence higher than 90% in adults aged 
between 25 to 44 years. It has also been reported that between 18% to 40% of CAP 
patients may test positive for tuberculosis, with over 50% of tuberculosis cases being 
in HIV-infected persons. The microbial etiology in HIV-infected patients with CAP may 
differ from HIV-uninfected individuals, with pneumococcus and tuberculosis being 
more frequent pathogens in HIV-infected patients. Pneumocystis infection was 
diagnosed in approximately 22% of HIV-infected adults admitted with CAP in sub-
Saharan Africa(40). 
Pneumococcal CAP in HIV-infected patients frequently presents with bacteremia and 
invasive pneumonia(3,6). In a Spanish study on the microbial etiology of CAP in HIV-
infected patients, 15% of the study population presented bacteremia, and 
pneumococcus was the main pathogen involved(4). In a study analyzing 129 HIV-
infected patients with CAP, Perello et al.(41) reported that 24% of patients presented 
bacteremia, and that the predictors of bacteremia were positive urinary antigen 
detection and the absence of ART in the multivariate analysis. 
Albrich et al.(42,43) have published two interesting studies on the nasopharyngeal 
colonization density of pneumococcus, measured by quantitative ART-PCR, and its 
relationship with diagnosis, severity, and outcomes of pneumococcal CAP in HIV-
infected patients. In their first study, a pneumococcal density cut-off of over 8000 
copies/mL for HIV-infected patients with CAP showed higher sensitivity and specificity 
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for diagnosed pneumococcal pneumonia. The second study demonstrated a 
correlation between nasopharyngeal colonization density and pneumococcal 
bacteremia, survival, and prognostic biomarkers in pneumonia.  
The main gram-negative bacterium involved in pneumonia in HIV-infected patients is 
Haemophilus influenzae, reported in under 7% of CAP cases in HIV-infected 
patients(4,6). 
Although pneumonia caused by Legionella is more common in patients with 
immunosuppressive conditions, it is rarely described in HIV-infected patients(44). 
Legionella pneumophila accounts for approximately 20% of all adult HIV-associated 
pneumonias, compared with 15% in the general population(45), and most information 
on this population is based on case reports(46–48). In a recent multicenter case-
control study (32 cases and 96 controls) conducted in Spain on the clinical presentation 
and outcomes of L. pneumophila CAP, no differences were found in clinical 
presentation or outcomes between cases and controls. The protective factors 
identified for developing L. pneumophila pneumonia in HIV-infected patients were 
undetectable viral load, higher CD4 cell counts, and use of ART in the multivariate 
analysis(49). 
Other intracellular pathogens causing CAP in HIV-infected patients include 
Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Coxiella burnetii(45). A 
recent study from Portugal of the microbial etiology of CAP in HIV-infected patients 
reported that M. pneumoniae was responsible for 8% and C. pneumoniae for 7% of 
CAP cases(39). Some studies have reported that the pulmonary infection rates of  M. 
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pneumoniae and C. pneumoniae are inversely proportional to the CD4 cell counts in 
HIV-infected patients(45,50). 
Despite the notable advances achieved with ART, HIV infection is a major risk factor for 
increased susceptibility to viral infection and for severe clinical presentation and worse 
outcomes. Respiratory viruses, especially influenza virus, represent a serious clinical 
event in HIV-infected patients above all in those with lower CD4 cell counts. Influenza 
is complicated in these patients with pneumonia or viral-bacterial co-infection. In the 
absence of ART, HIV patients have an increased risk of hospitalization, mortality, and 
prolonged illness due to influenza infection when compared with the general 
population(51,52). During the H1N1 influenza pandemic of 2009, between 1% and 6% 
of the hospitalized cases were HIV-infected patients. A study from Mexico describing 
the clinical course of infection by 2009 (H1N1) influenza virus at different stages of HIV 
found the infection to be more severe in HIV-infected patients with late and advanced 
HIV disease than in well-controlled patients on ART(53). In a Spanish study of more 
than 600 HIV-infected patients on ART with influenza A H1N1, the severity of influenza 
A H1N1 infection in HIV-infected patients on ART did not increase, and influenza A 
H1N1 infection did not have a major effect on HIV infection(54). 
In conclusion, the distribution of pathogens in bacterial CAP differs according to the 
use of ART. Overall, S. pneumoniae, P. jirovecii, H. influenza and respiratory viruses 
remain the most common pathogens causing CAP in HIV-infected patients.  
6. Microbiome in HIV-infected patients 
New culture-independent methods have shown that the lungs, previously thought to 
be sterile, instead host a diversity of microbial communities collectively known as the 
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“lung microbiome”. These communities exist in the absence of infection and are 
modified by several external and internal factors. In a recently published study on the 
potential role of airway microbiota in dictating immune responses and infection 
outcomes in 182 HIV-associated pneumonia cases, Shenoy et al.(55) reported that 
compositionally and structurally distinct lower airway microbiomes were associated 
with discrete local host immune responses, peripheral metabolic reprogramming, and 
different mortality rates. Similarly, in a study on the relationship between respiratory 
microbiota and metabolic profiles in bronchoalveolar lavage (BAL) fluid from 39 HIV-
infected outpatients and 20 HIV-uninfected outpatients, Cribbs et al.(56) reported that 
specific metabolic profiles in BAL samples correlated with bacterial organisms that are 
known to play a role in the pathogenesis of pneumonia in HIV-infected patients. 
In another interesting study, Iwai et al.(57) investigated respiratory bacterial 
communities associated with acute pneumonia in HIV-infected patients. The authors 
compared oral and airway samples in a cohort of HIV-infected patients during the 
course of antimicrobial therapy for pneumonia, and compared the airway microbiota 
of HIV-infected and uninfected patients with acute pneumonia on antimicrobial 
therapy.  The oral bacterial burden was 2.80 x 106 copies per 20 ng of DNA, whereas 
the airway bacterial burden was 5.43 x 103 copies per 20 ng of DNA. In oral samples, 
1,754 taxa, representing 42 phyla and 153 families, were detected in at least one of 
the 15 HIV-infected patients. In airway samples 1,654 taxa representing 41 phyla and 
152 distinct families were detected in at least one of the 15 samples; of those, 194 taxa 
were detected in more than 80% of patients including members of the 
Sphingomonadaceae, Campylobacteraceae, and Helicobacteracea. Twenty-two taxa 
belonging to the phyla Actinobacteria, Bacteroidetes, Chloroflexi, Cyanobacteria, 
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Firmicutes, and Natronoanaerobium were common to the oral and airways niche in all 
patients and included Streptococcus bovis and Chryseobacterium species. These data 
suggest that HIV-infected patients exhibit a relatively high abundance of a large 
number of phylogenetically distinct taxa, which include pathogenic organisms, 
suggesting that recurrent pneumonia in the HIV-infected population may be related to 
the presence of these species. 
In the near future, better knowledge and understanding of the lung (and gut) 
microbiome will shed light on the physiopathology, treatment, and prevention of CAP. 
7. Assessment of severity and making site-of-care decisions 
Several instruments such as the Pneumonia Severity Index (PSI) and the CURB-65 
(Confusion, Urea, Blood Pressure and Age 65) criteria to predict short-term mortality 
have been developed to render hospitalization decisions more objective in the general 
population(58,59). In addition, the IDSA/ATS 2007 criteria(60), has been developed to 
determine ICU admission in the general population. However, few studies have 
evaluated the applicability of these instruments in the HIV-infected population(61,62). 
Curran et al.(61) evaluated the PSI score and reported that it accurately predicted 
high-risk pneumonia and mortality. The authors also suggested that combining the 
CD4 cell count and PSI score would help physicians decide which patients required 
hospitalization. The study by Albrich et al.(42), which analyzed the association between 
nasopharyngeal S. pneumoniae densities in HIV-infected patients from South Africa 
with markers of severity and poor outcomes, reported no correlation between CURB-
65 and mortality in these patients. However, the study by Almeida et al.(62) 
investigated the use of CURB65 in HIV-infected patients, and reported that a higher 
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CURB65 score and a CD4 count lower than 200 cells/mL were both associated with 
worse outcomes. They concluded that the CURB65 score plus CD4 cell count could be 
used in HIV-infected patients with CAP. 
In conclusion, the combined use of severity scores such as PSI or CURB65 and CD4 cell 
count should help clinicians to determine the severity of bacterial CAP in HIV-infected 
patients (Figure 2).  
8. Antibiotic therapy 
Antibiotic therapy in HIV-infected patients with CAP does not differ significantly from 
that administered to the general population. Nevertheless, current pneumonia 
guidelines do not specifically include the HIV-infected population(60,63), suggesting 
that treatment should be similar to that for the general population. Although HIV-
infected patients on ART show an improved immune response, CD4 reconstitution, and 
viral suppression, these patients are still at higher risk of pneumonia in part because 
they show altered immunity and because immune activation persists even when 
receiving ART(7). 
The empiric antibiotic therapy for CAP should cover the main pathogens that cause 
pneumonia, including S. pneumoniae and intracellular bacteria (C. pneumoniae, C. 
burnetii, M. pneumoniae and L. pneumophila) and should be modified according to the 
antibiotic susceptibility report. Current international guidelines suggest the use of 
macrolide or doxycycline in healthy outpatients without risk of drug-resistant S. 
pneumoniae, and a fluoroquinolone or β-lactam plus macrolide in outpatients with risk 
of drug-resistant S. pneumoniae.  
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A β-lactam plus a macrolide, or a β-lactam plus a fluoroquinolone, or a fluoroquinolone 
alone should be as empiric treatment for hospitalized patients (in the ICU or general 
ward), but fluoroquinolone monotherapy should be restricted to non-ICU 
patients(40,60). However, few randomized controlled trials (RCT) have investigated 
these antibiotic regimens and most of the information available comes from 
retrospective observational analyses. 
In a recent randomized controlled trial published by Figueiredo-Mello et al.(64) on the 
use of ceftriaxone monotherapy versus ceftriaxone plus macrolide in HIV-infected 
patients with CAP, it was observed that the combination did not improve patient 
outcomes. However, in that study not all patients who met the inclusion criteria were 
enrolled in the trial. In addition, the first dose of the assigned regimen was 
administered within the first 48 hours of hospitalization; these circumstances may 
have influenced the results of the study. 
In contrast, a prospective observational international multicenter study that included 
844 adult HIV-infected and uninfected patients with pneumococcal bacteremia found 
that combination therapy was associated with a lower 14-day mortality rate in only 
severely ill patients (23% versus 55%; p = 0.015)(65) but there were no significant 
differences between the two groups. A potential explanation for these results is the 
fact that macrolides not only inhibit bacterial protein synthesis, but are also potent 
inhibitors of the production of pneumolysin and reduce the adherence of 
pneumococcus to respiratory epithelium. 
In regions where M. tuberculosis is common we must exercise caution regarding 
fluoroquinolone monotherapy, since its use in M. tuberculosis cases may render the 
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sputum culture negative due to the rapid clearance of the pathogen in the sputum 
sample and the development of fluoroquinolone resistance in the isolates. 
 
 
9. Drug interactions between ART and CAP antibiotic therapy 
Drug-drug interactions (DDI) present significant risks to patients and are a challenge 
for health care providers. However, there is no interaction between ART families and 
penicillins, beta-lactams inhibitors or levofloxacin. Moxifloxacin has a low interaction 
with atazanavir and lopinavir (protease inhibitors): it has been shown to prolong the 
QT interval, and so care should be taken especially in patients with pre-existing risk 
factors (bradycardia, long congenital QT, electrolyte imbalances, and so on).  
Azithromycin may cause abnormal changes in the electrical activity of the heart and 
can induced QTc interval prolongation and Torsade de pointes. This adverse event 
should be taken into account when antiretrovirals can increase its exposure (like 
ritonavir-boosted protease inhibitors) or can also increase QT interval (rilpivirine). 
Azithromycin is mainly eliminated via biliary excretion and animal data suggest this 
may occur via P-glycoprotein and MRP2. Ritonavir-boosted regimens could potentially 
increase azithromycin exposure (inhibition of P-glycoprotein and MRP2); however, no 
a priori dosage adjustment is recommended for azithromycin. Cobicistat is not 
expected to inhibit hepatic P-gp and MRP2 at clinically relevant concentrations and can 
be given concomitantly with azithromycin. Rilpivirine (an NNRTIs drug) should be used 
with caution when co administered with a drug with a known risk of Torsade de 
Pointes. In healthy subjects, supra-therapeutic doses of rilpivirine (75 mg once daily 
and 300 mg once daily) have been shown to prolong the QTc interval.  
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Clarithromycin can also prolong the QT interval and increase the risk of life-threatening 
arrhythmias. Clarithromycin is metabolized by CYP3A4 and its concentrations are 
increased due to inhibition of CYP3A4 by ritonavir or cobicistat-based ART 
regimens. Ritonavir increases clarithromycin AUC and Cmax by 77% and 31%, 
respectively. Clarithromycin should be avoided in patients with long QT syndrome, 
cardiac disease, or in patients taking other QT-prolonging medications, such as 
rilpivirine. Because clarithromycin has many and different types of DDI with all classes 
of antiretrovirals (protease inhibitors, NNRTIs, entry and integrase inhibitors and 
nucleoside/tide analogues [NRTI]), it is preferable to use azithromycin instead of 
clarithromycin because of its better DDI profile. 
We recommend these two links for more updated information on DDI between the 
antimicrobials used to treat pulmonary infections and antiretroviral drugs: 
 https://www.hiv-druginteractions.org/checker (English Web site); 
http://www.interaccionesvih.com/interaccions.html (Spanish Web site)  
 
 10. Prognosis of Bacterial CAP in HIV-infected patients 
In a recent study of 806 patients admitted to the medical and surgical ICUs at Groote 
Schuur Hospital, Cape Town, South Africa over the course of one year (66), 77 were 
HIV-positive (9.6%), and the main cause of ICU admission was CAP. The same authors 
reported that ICU mortality was 25% and hospital mortality was 35%. These data 
clearly demonstrate that CAP is a major cause of morbidity and mortality among HIV-
infected persons, especially in those not receiving ART – a very frequent situation in 
the geographical region where this study was conducted. 
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Bacterial CAP mortality in HIV-infected patients in the post-ART era has been reported 
to range between 6% and 15% (4,7). Despite the high rate of bacterial pneumonia in 
HIV-infected patients, mortality rates are not higher than in non-HIV-infected 
patients(5,10,19,67). The risk factors reported associate with higher mortality are 
neutropenia, a CD4 cell count of < 100 cells per mm3, a Karnofsky score of ≤ 50, LDH ≥ 
598 U/L, mechanical ventilation, a partial pressure of oxygen < 70 mmHg, shock, and 
radiographic progression of disease(4,19,38). 
In a retrospective study from Italy, the authors studied 84 bacterial CAP episodes in 76 
HIV-infected inpatients. The proportion of patients receiving ART was 42% whereas 
58% of HIV-infected patients were not treated. Although the time to clinical stability 
was longer in patients without ART (1.9 ± 7.9 vs. 7.6 ± 5.4 days; p = 0.01), the author 
did not observe differences in mortality between HIV-infected patients with or without 
ART (44% vs. 55%) because of the small sample size(19). 
In a case-control study from the USA that aimed to determine differences in clinical 
outcomes between hospitalized HIV-positive and HIV-negative patients with CAP, 
Christensen et al. (11) found no differences in time to clinical stability, length of 
hospitalization, or mortality, and concluded that clinical outcomes for hospitalized 
patients with CAP may not be influenced by HIV infection. Patients were matched for 
age and the mortality risk was determined by the PSI score. However, two main 
limitations in this study should be noted: the small sample size, and the lack of data on 
the CD4 cell count for 36% of the population.  Additionally, Bordon et al. (67) reported 
that clinical outcomes for HIV-infected patients with CAP were not predicted by CD4+ 
cell counts or HIV-RNA levels in a cohort of North American patients.  
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The data on clinical presentation and outcomes of pneumococcal CAP in HIV-infected 
patients are conflicting. Clinical variables in HIV-infected patients are difficult to 
compare with those of non-HIV-infected patients, as bacterial pneumonia often occurs 
at later ages in non-HIV-infected patients  than in the HIV population(68,69). In 2007, a 
study investigated the clinical and laboratory features, hospital course and outcome of 
HIV with non-HIV patients with bacteraemic pneumococcal pneumonia. In the analysis 
of 768 cases with bacteraemic pneumococcal CAP, 14-day mortality was 16% in the 
HIV patients and 13.9% in the non-HIV patients (a non-significant difference). When 
adjustments were made for age and severity of pneumonia, HIV patients had 
significantly higher 14-day mortality, with a significant trend towards increased 14-day 
mortality in those with lower CD4 counts(15). 
However, a recent Spanish study on clinical outcomes of pneumococcal CAP in 
virologically suppressed, HIV-infected patients on ART with a CD4+ T-cell count > 350 
cells/mm3 compared with uninfected patients with CAP found similar outcomes 
between HIV-infected and uninfected patients with pneumococcal CAP(9). 
Recent years have witnessed changes in the demography of the HIV-infected 
population, especially as regards age. In a recent study by Barakat et al.(70) comparing 
clinical outcomes in HIV-infected and uninfected older men hospitalized for CAP, the 
authors use the Veterans Aging Cohort Study (VACS) Index, which is a validated 
predictor of all-cause mortality in HIV-infected patients and also predicts 30-day 
mortality for both HIV-infected and uninfected patients admitted to the ICU(70–72). 
The VACS Index score was significantly higher among the HIV-infected patients 
compared with the uninfected patients [mean 32.7 (SD 19.4) versus 27.2 (SD 17.5; p < 
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0.001], and the majority of the HIV-infected patients had CD4 counts < 500 cells/μL 
and HIV viral loads < 500 copies/mL and were on ART. The median VACS Index score 
was 58, and the adjusted mortality rate was 18.4 (95% CI 6.6, 51.3)/1000 person-
months for those on ART versus 73.6 (95% CI 24.8, 218.5)/1000 person-months for 
those not on ART. The authors concluded that the VACS Index was associated with 
adverse clinical outcomes. ART was associated with a lower 30-day mortality and 
length of hospital stay(70) in the multivariate analysis. 
11. Prevention 
Several interventions can reduce the risk of CAP in HIV-infected adults, especially 
smoking cessation, reduced alcohol consumption, ART initiation in patients with CAP, 
early diagnosis of HIV infection, and programs to help with ART compliance in non-
compliant patients(23,70). 
The risk and severity of pneumococcal pneumonia and influenza complications are 
higher in HIV-infected individuals(73). Vaccination constitutes an important strategy to 
ensure the health of HIV-infected persons, and an annual influenza vaccination —
regardless of CD4 count — is the main recommendation for HIV-infected patients given 
by advisory groups in Europe(74–76) and the US (77–79), and by the WHO. 
The European AIDS Clinical Society (EACS) advises the administration of pneumococcal 
vaccination for all HIV-positive persons(75) as follows: One dose of conjugated 13-
valent vaccine (PCV-13) for all individuals, even when pre-vaccinated with PPV-23 
polysaccharide vaccine. No general recommendation has been given for a booster 
dose. The Advisory Committee on Immunization Practice (ACIP) and the Infectious 
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Diseases Society of America (IDSA) guidelines(78,80) recommend PCV13 followed by 
PPSV23 in HIV-infected patients. 
In a recently published randomized clinical trial investigating immunological response 
to PCV13 followed by PPSV23 versus PPSV23 in HIV-infected adults, Sadlier et al.(81) 
found that combining PCV13 with PPSV23 elicited a greater magnitude of IgG and 
(OPA) immune response compared to PPSV23 alone in HIV-infected individuals with a 
CD4 count > 200 cells/mm3 over the study period. The result of this study supports the 
current pneumococcal vaccination recommendations in the United States and Europe 
for HIV-infected persons. 
In previously unvaccinated individuals, the recommendation is one dose of PCV13 
followed by one dose of PPV23 ≥ 8 weeks later (preferably when the CD4 count ≥ 200 
cells/mm3), repeating the PPV23 dose 5 years later. In persons previously vaccinated 
with PPV23, the recommendation is to give PCV13 at ≥ 1 year later followed 5 years 
later by PPV23(82). 
12. Conclusions 
Community-acquired pneumonia in HIV-infected patients is a major cause of 
morbidity, and mortality. However, the management and outcomes of bacterial CAP in 
HIV-infected persons on ART are similar to those in uninfected persons, suggesting that 
the management should be the same for both populations. 
13. Expert commentary 
Recent studies have reported that despite ART, bacterial CAP remains a major cause of 
disease, health costs, and mortality in the HIV-infected population, especially in high-
income countries. However, in middle and low-income countries tuberculosis remains 
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the main cause of pulmonary disease and bacterial pneumonia is the second most 
important cause of lung infections. Despite improvements in the accessibility to ART it 
is not yet available to millions of HIV-infected people, especially in developing 
countries. 
Since pneumococcal pneumonia is the most frequently occurring bacterial infection in 
HIV-infected persons on ART and is associated with higher mortality rates, preventive 
strategies such as smoking cessation programs and vaccination campaigns are 
essential. Also, we recommend that since HIV is diagnosed in many cases of CAP, all 
suspected cases of CAP should be tested for HIV. 
Early identification of HIV infection is mandatory, especially in those geographical 
areas most affected by this pandemic, in order to start effective ART therapy and 
improve the quality of life of affected persons. 
14. Five-year view 
CAP in the HIV-infected population is a major health problem worldwide. Since HIV-
infected patients are surviving longer than those who were ill before the advent of 
ART, we will observe changes in the epidemiology of CAP. In future clinical practice, 
multidisciplinary specialist teams will be required for the management of HIV-infected 
patients with pneumonia in order to improve patient outcomes. Further clinical 
research is needed in order to provide more complete information that will help 
management of CAP in this specific population. Furthermore, continuous smoking 
cessation programs and vaccination campaigns will effectively help prevent bacterial 
CAP in the HIV-infected population. National and international guidelines should be 
based on current knowledge of pneumonia in HIV-infected patients in order to 
disseminate research data worldwide 
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15. Key issues 
• Despite ART, bacterial pneumonia remains a major cause of disease in the HIV-
infected population. 
• Streptococcus pneumoniae is the most frequently detected pathogen causing 
bacterial CAP in HIV-infected patients on ART. Tuberculosis and Pneumocystis 
infection are the prevalent pathogens in geographical areas with a lower rate of 
HIV diagnosis and no ART therapy. 
• The clinical presentation and management of bacterial CAP is similar in HIV-
infected patients on ART and uninfected patients. 
• In HIV virologically suppressed patients on ART with > 350 CD4+ T-cell 
count/mm3 clinical outcomes are similar to the general population. We 
recommend that such patients do not need treatment, admission, or care sites 
that differs from that of the general population. 
• Bacterial CAP prevention measures such as smoking cessation and vaccination 
campaigns are crucial in the HIV-infected population. 
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Table 1. Risk factors associated with bacterial CAP in HIV-infected patients 
Risk factors Evidence Suggested Intervention 
 
*Smoking (current and 
passive) 
 
*Risk of CAP increased in current, 
former and passive smokers 
 
* Smoking cessation 
 
*Abuse of alcohol 
consumption 
 
*Higher consumption of alcohol 
(≥80 g/L) is a risk factor for CAP. 
Alcohol exposure (chronic heavy 
drinking) affects all components 
of the adaptive immune system. 
 
* Reduce alcohol 
consumption 
 
*Injecting drug use 
 
*High incidence of bacterial CAP 
due to poor adherence to ART and 
lower socioeconomic status 
 
* Programs to control drug 
use 
 
*Older age  
 
*CAP incidence increases 
significantly with advanced age. 
Immunological changes that 
decreased efficiency of the 
adaptive and innate immune 
systems: “immunosenescence”. 
 
 
*Malnutrition 
 
* Underweight is associated with 
increased risk of CAP 
 
* Dietary advice  
 
*Detectable viral load and 
lower CD4 cell count 
 
*Suppressed HIV loads are 
associated with a lower incidence 
of CAP. 
 
*Compliance with ART and 
following periodical control 
 
*Comorbidities  
 
*Chronic respiratory diseases, 
chronic cardiovascular disease, 
diabetes mellitus, chronic liver or 
renal disease increase the risk of 
CAP 
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*Not vaccinated against 
influenza and Streptococcus 
pneumoniae 
 
*Recommendations of 
international societies 
*Ensure compliance with 
vaccination 
References: 2,3,9,13,14,15,17,18,19,20,22,23,24,25,27,28,29,30,62,63,66,67,68,70,71 
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